NCT04495348View on ClinicalTrials.gov

Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance

CompletedOBSERVATIONAL
Enrollment

18

Participants

Timeline

Start Date

October 22, 2020

Primary Completion Date

January 25, 2023

Study Completion Date

June 5, 2023

Conditions
HIV-1-infectionWeight Gain
Interventions
DRUG

Doravirine

Participants will be switched to doravirine and then switched back to INSTI-based therapy to determine the impact on energy balance.

Trial Locations (2)

77030

UTHealth, Houston

80045

University of Colorado Anschutz Medical Campus, Aurora

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Colorado, Denver

OTHER

NCT04495348 - Explorations Into the Mechanism for INSTI-associated Weight Gain: a Focus on Energy Balance | Biotech Hunter | Biotech Hunter